Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of GB-5001A vs Aricept in Healthy Subjects
NCT07799090Phase 1Completed
- Sponsor
- G2GBIO
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1 trial of GB-5001A in Alzheimer's disease (AD) (3 arms), sponsored by G2GBIO. Primary endpoint: Pharmacokinetic parameter at 226 days. Started Aug 2025; status: completed.
02
Drugs
GB-5001A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07799090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799090.